Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 44 of 66 · 3126 articles
This study identifies a plant-derived compound that reduced inflammation and promoted intestinal healing in mouse models by modulating the Wnt/β-catenin pathway and ILC3-driven IL-22 production—pathways relevant to...
XOR is linked to oxidative stress, inflammation, drug (thiopurine) metabolism, microbiome interactions, and inflammation-associated colorectal cancer — all processes relevant to IBD pathogenesis and complications....
People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...
The study links patient-specific non-coding genetic variation to epithelial regulatory networks and to differences in disease severity and response in a large UC trial, suggesting genetics could help explain why some...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
This review describes a novel, targeted microbiome approach (phage therapy) aimed at bacteria linked to Crohn’s disease. If effective and proven safe in trials, phage therapy could offer a more precise way to reduce...
This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
Epigenetic control of intestinal epithelial cells can shape gut microbes and influence colitis severity; understanding SETD2’s role could point to new mechanistic targets for IBD research and microbiome-directed...
Researchers found that immune cells detect the gut-associated yeast Debaryomyces hansenii via Dectin-1 and Card9, and the yeast was enriched in Crohn’s disease ulcers. That suggests a possible microbial–immune link...
If epithelial cells themselves retain disease-linked programs, that could help explain persistent intestinal abnormalities in Crohn’s disease even during remission and point to new biomarker or therapeutic targets...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Genetics and genomics. The original article is from msn.com.
The work helps bridge genetic association signals and the specific immune cells in the intestine where they may act, offering new candidate genes and a method that can probe rare cell types important to IBD biology.
ILC3s live in the intestine and help regulate barrier function and inflammation, so mapping how genetic variants affect gene regulation in these rare cells helps connect inherited risk signals to plausible biology for...
Mapping 3D genome contacts in rare gut immune cells connects Crohn’s disease genetic risk variants to specific genes and pathways, which can clarify disease mechanisms and guide future drug-target research. The study...
ILC3s are rare but important for gut immunity; linking Crohn’s disease genetic risk to the genes they regulate helps move from statistical association toward biological mechanisms that could explain disease pathways.
This study helps move beyond assigning GWAS risk variants to the nearest gene by mapping 3D promoter contacts in gut-enriched ILC3s, so it uncovers new candidate genes and pathways that could explain Crohn’s and other...
The study helps explain how noncoding genetic variants may influence Crohn’s disease by altering 3D genome interactions in rare gut-associated immune cells (ILC3s), pointing to new genes and pathways that could be...
Researchers are exploring new antioxidant nanozymes that can be given orally to reduce intestinal inflammation in lab models. If these approaches eventually translate to humans, they could become an additional strategy...
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
This research links a specific gut-associated yeast to activation of innate immune pathways (Dectin-1–Card9) that drive inflammatory signaling. For people with Crohn disease, it suggests fungal members of the gut...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemistry and Biophysics Reports.
People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...
This trial tests a new oral drug (Alpha-0261) for moderate-to-severe ulcerative colitis and could matter to people who haven’t responded to standard medicines. Early-phase studies mainly assess safety but also collect...
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
New drugs in mid-stage trials may expand treatment options for people with moderate to severe Crohn's disease, especially those who have not responded to existing therapies. This trial is measuring clinical remission at...
EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
People with Crohn’s disease may benefit from research that identifies the specific genes and immune pathways driving inflammation — this study points to over 100 genes in gut ILC3 cells that could explain how genetic...
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
The appendix in conventional UC appears to be inflamed early and then remodels to fibrous obliteration over decades, which could influence thinking about timing or rationale for appendectomy-based interventions.
Krill oil improved colitis signs and intestinal barrier markers in a mouse model and changed colon gene expression linked to cell adhesion—findings that may interest people tracking dietary or supplemental approaches for...
The study links a common environmental pollutant (UV-328) to worsened experimental colitis and altered cholesterol metabolism, suggesting environmental exposures might influence IBD activity and could point to new...
MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...
Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
The review suggests that allergic-type (type 2) immune pathways may play a meaningful role in some people with Crohn's disease, which could point to new treatment options that target IgE, Th2 cytokines, epithelial...
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
This review suggests SSRIs and SNRIs may influence both brain and gut pathways relevant to symptom burden in IBD and DGBI — potentially improving mood, pain, motility, and aspects of inflammation. That could matter for...
The study identifies Gardenia-derived pectic polysaccharides that reduced inflammation and restored colon health in a mouse colitis model, suggesting a possible microbiome-mediated protective effect relevant to IBD...
The study explores a multi-herb formula that the authors report reduces inflammation and alters gut microbiota in a mouse model of ulcerative colitis, suggesting possible biological mechanisms worth further study.
The study identifies macrophage-derived microvesicles as modulators of intestinal barrier function and ER stress in ulcerative colitis models, suggesting a new mechanism that could be relevant to mucosal healing...
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
